| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/18/2010 | CA2734095A1 Coated tablets with a remaining degradation surface over the time |
| 02/18/2010 | CA2734082A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | CA2734077A1 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | CA2733970A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |
| 02/18/2010 | CA2733966A1 Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
| 02/18/2010 | CA2733941A1 Bicyclic triazole derivatives for the treatment of tumours |
| 02/18/2010 | CA2733931A1 Composition and methods for the design and development of metallo-enzyme inhibitors |
| 02/18/2010 | CA2733930A1 Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore |
| 02/18/2010 | CA2733926A1 Therapeutic compounds |
| 02/18/2010 | CA2733922A1 A crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| 02/18/2010 | CA2733920A1 A new crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| 02/18/2010 | CA2733918A1 The treatment of hearing loss |
| 02/18/2010 | CA2733907A1 Methods for enhancing energy metabolism |
| 02/18/2010 | CA2733905A1 Compositions and methods for influencing satiety, lipid metabolism, and fat utilization |
| 02/18/2010 | CA2733787A1 Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
| 02/18/2010 | CA2733780A1 Gentle, non-irritating, non-alcoholic skin disinfectant |
| 02/18/2010 | CA2733778A1 Stabilized pharmaceutical composition |
| 02/18/2010 | CA2733775A1 Agent for promoting neuronal differentiation and method therefor |
| 02/18/2010 | CA2733762A1 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
| 02/18/2010 | CA2733750A1 Novel adenine derivatives |
| 02/18/2010 | CA2733749A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 02/18/2010 | CA2733743A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 02/18/2010 | CA2733686A1 Aabb-poly(depsipeptide) biodegradable polymers and methods of use |
| 02/18/2010 | CA2733651A1 Pharmaceutical formulation for reducing pulmonary blood pressure |
| 02/18/2010 | CA2733646A1 Acetyl pyrrolidinyl indole derivative |
| 02/18/2010 | CA2733611A1 Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| 02/18/2010 | CA2733588A1 N-heterocyclic m1 receptor positive allosteric modulators |
| 02/18/2010 | CA2733556A1 A micro-rna that promotes vascular integrity and uses thereof |
| 02/18/2010 | CA2733553A1 Local anti-infective agent for treatment of nail fungal infections |
| 02/18/2010 | CA2733523A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a .beta.2-adrenoceptor agonist |
| 02/18/2010 | CA2733509A1 Antimicrobial silver solutions |
| 02/18/2010 | CA2733449A1 2-hydroxy-ethanesulfonate salt |
| 02/18/2010 | CA2733447A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient |
| 02/18/2010 | CA2733445A1 Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use |
| 02/18/2010 | CA2733397A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | CA2733247A1 Heterocyclic amide derivatives as ep4 receptor antagonists |
| 02/18/2010 | CA2733190A1 Oxadiazole-2-oxides as antischistosomal agents |
| 02/18/2010 | CA2733128A1 Chymase inhibitors |
| 02/18/2010 | CA2732931A1 Amorphous ambrisentan |
| 02/18/2010 | CA2732922A1 2-amino pyrimidine compounds as potent hsp-90 inhibitors |
| 02/18/2010 | CA2732881A1 Composition that comprises crystallisation inhibitory substances |
| 02/18/2010 | CA2732809A1 Aptamer inhibition of thrombus formation |
| 02/18/2010 | CA2732789A1 Treatment of pulmonary arterial hypertension |
| 02/18/2010 | CA2732784A1 Compositions comprising terpene compounds for treating negative sensory phenomena |
| 02/18/2010 | CA2732210A1 Monoaryl aminotetralines |
| 02/18/2010 | CA2731946A1 Flavin derivatives |
| 02/18/2010 | CA2731941A1 Antifungal agents |
| 02/18/2010 | CA2731696A1 Antifungal agents |
| 02/18/2010 | CA2731370A1 Therapeutic compositions containing macitentan |
| 02/18/2010 | CA2731353A1 Stable injectable oil-in-water docetaxel nanoemulsion |
| 02/18/2010 | CA2731108A1 Cmet inhibitors |
| 02/18/2010 | CA2731102A1 Imine derivatives as cannabinoid receptor ligands |
| 02/18/2010 | CA2728451A1 Salicylamide derivatives as nicotinic alpha 7 modulators |
| 02/17/2010 | EP2154248A1 Compounds and methods for diagnosis of tuberculosis |
| 02/17/2010 | EP2154144A1 Oligonucleotides and use thereof |
| 02/17/2010 | EP2154139A1 Bicyclic heterocyclic compound |
| 02/17/2010 | EP2154138A1 Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof |
| 02/17/2010 | EP2154137A1 Crystalline form of moxifloxacin base |
| 02/17/2010 | EP2154136A1 Quinuclidine carbonate derivatives and medicinal compositions thereof |
| 02/17/2010 | EP2154135A1 Therapeutic agent for cerebral infarction |
| 02/17/2010 | EP2154131A1 G protein-coupled receptor inhibitor and pharmaceutical product |
| 02/17/2010 | EP2154130A1 Pyridone compound |
| 02/17/2010 | EP2154127A2 Conversion of hydrocyanated unsaturated carboxylic acid derivatives into amines |
| 02/17/2010 | EP2153870A1 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| 02/17/2010 | EP2153849A2 Contraception process and administration form for the same |
| 02/17/2010 | EP2153847A1 Gene sensitive to bone/joint disease and use thereof |
| 02/17/2010 | EP2153843A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/17/2010 | EP2153839A1 Composition for prevention and/or treatment of peptic ulcer |
| 02/17/2010 | EP2153838A1 Anti-norovirus agent, and composition comprising the same |
| 02/17/2010 | EP2153836A1 Film-forming liquid formulations for drug release to hair and scalp |
| 02/17/2010 | EP2153834A2 Extended release pharmaceutical compositions comprising quetiapine salts |
| 02/17/2010 | EP2153833A1 ADP-receptor antagonist for treatment of inflammatory disease |
| 02/17/2010 | EP2153832A2 Heterocyclic aspartyl protease inhibitors |
| 02/17/2010 | EP2153831A1 Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient |
| 02/17/2010 | EP2153830A1 Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
| 02/17/2010 | EP2153829A1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 02/17/2010 | EP2153828A2 Composition for the Transdermal Delivery of Fentanyl |
| 02/17/2010 | EP2153827A2 Composition for the Transdermal Delivery of Fentanyl |
| 02/17/2010 | EP2153825A1 Therapeutic formulation for administering tolterodine with controlled release |
| 02/17/2010 | EP2153824A1 Seamless multiparticulate formulations |
| 02/17/2010 | EP2153822A1 Granulation of active pharmaceutical ingredients |
| 02/17/2010 | EP2153821A1 Oral formulations of camptothecin derivatives |
| 02/17/2010 | EP2153820A1 Liposome and method for producing liposome |
| 02/17/2010 | EP2153819A2 Compositions containing therapeutically active components having enhanced solubility |
| 02/17/2010 | EP2153814A1 Use of compositions comprising urea |
| 02/17/2010 | EP2152879A2 Rna antagonist compounds for the modulation of beta-catenin |
| 02/17/2010 | EP2152874A2 Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| 02/17/2010 | EP2152860A2 Peptide linked cell matrix materials for stem cells and methods of using the same |
| 02/17/2010 | EP2152811A1 Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics |
| 02/17/2010 | EP2152722A2 Compositions comprising mir34 therapeutic agents for treating cancer |
| 02/17/2010 | EP2152719A1 Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 02/17/2010 | EP2152714A1 Spiroindolinone derivatives |
| 02/17/2010 | EP2152713A1 Pyrazolopyrrolidines as inhibitors of gamma secretase |
| 02/17/2010 | EP2152710A2 4,4-disubstituted piperidine derivatives |
| 02/17/2010 | EP2152709A1 Morphinan compounds |
| 02/17/2010 | EP2152707A1 [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
| 02/17/2010 | EP2152706A1 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use |
| 02/17/2010 | EP2152705A1 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| 02/17/2010 | EP2152704A1 Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
| 02/17/2010 | EP2152702A1 Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer |